See more : Enterra Corporation (ETER) Income Statement Analysis – Financial Results
Complete financial analysis of Lantheus Holdings, Inc. (LNTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantheus Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- KTMG Limited (XCF.SI) Income Statement Analysis – Financial Results
- Railcare Group AB (publ) (RAIL.ST) Income Statement Analysis – Financial Results
- Nanjing Quanxin Cable Technology Co., Ltd. (300447.SZ) Income Statement Analysis – Financial Results
- Avricore Health Inc. (AVCR.V) Income Statement Analysis – Financial Results
- Lexibook – Linguistic Electronic System Société anonyme (ALLEX.PA) Income Statement Analysis – Financial Results
Lantheus Holdings, Inc. (LNTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lantheus.com
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 935.06M | 425.21M | 339.41M | 347.34M | 343.37M | 331.38M | 301.85M | 293.46M | 301.60M | 283.67M | 288.11M | 356.29M |
| Cost of Revenue | 586.89M | 353.36M | 237.51M | 200.65M | 172.53M | 168.49M | 169.24M | 164.07M | 157.94M | 176.08M | 206.31M | 212.91M | 261.08M |
| Gross Profit | 709.54M | 581.70M | 187.70M | 138.76M | 174.81M | 174.89M | 162.14M | 137.78M | 135.52M | 125.52M | 77.36M | 75.20M | 95.22M |
| Gross Profit Ratio | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% | 46.18% | 41.62% | 27.27% | 26.10% | 26.72% |
| Research & Development | 77.71M | 311.68M | 44.97M | 32.79M | 20.02M | 17.07M | 18.13M | 12.20M | 14.36M | 13.67M | 30.46M | 40.60M | 40.95M |
| General & Administrative | 125.46M | 133.58M | 150.40M | 69.27M | 61.24M | 50.17M | 49.84M | 38.83M | 43.89M | 37.31M | 33.04M | 32.52M | 32.86M |
| Selling & Marketing | 141.74M | 100.24M | 68.42M | 40.90M | 41.89M | 43.16M | 42.32M | 36.54M | 34.74M | 35.12M | 35.23M | 37.44M | 38.69M |
| SG&A | 267.19M | 233.83M | 218.82M | 110.17M | 103.13M | 93.33M | 92.16M | 75.37M | 78.63M | 72.43M | 68.26M | 69.96M | 71.55M |
| Other Expenses | 0.00 | -1.70M | -7.35M | 2.20M | -6.22M | 2.47M | 8.64M | 220.00K | -89.00K | 3.00K | 9.25M | 34.80M | 205.00K |
| Operating Expenses | 344.90M | 545.51M | 263.78M | 142.96M | 123.15M | 110.40M | 110.28M | 87.58M | 92.99M | 86.10M | 98.72M | 110.56M | 112.50M |
| Cost & Expenses | 931.79M | 898.87M | 501.30M | 343.61M | 295.68M | 278.89M | 279.53M | 251.65M | 250.93M | 262.18M | 305.03M | 323.47M | 373.57M |
| Interest Income | 19.64M | 2.61M | 45.00K | 238.00K | 686.00K | 167.00K | 18.00K | 0.00 | 24.00K | 27.00K | 104.00K | 252.00K | 333.00K |
| Interest Expense | 20.02M | 7.19M | 7.75M | 9.48M | 13.62M | 17.41M | 18.41M | 26.62M | 38.72M | 42.29M | 42.92M | 42.01M | 37.66M |
| Depreciation & Amortization | 60.04M | 47.93M | 42.29M | 24.69M | 13.38M | 13.86M | 19.14M | 18.26M | 19.65M | 18.25M | 25.16M | 27.40M | 32.76M |
| EBITDA | 491.01M | 81.83M | -25.00M | 22.69M | 55.62M | 80.81M | 77.19M | 73.18M | 46.59M | 58.17M | 7.53M | 26.86M | 17.74M |
| EBITDA Ratio | 37.87% | 3.69% | -19.62% | -0.59% | 13.08% | 19.50% | 18.25% | 16.70% | 14.47% | 19.13% | 4.63% | 9.40% | 4.50% |
| Operating Income | 364.64M | -13.44M | -76.09M | -4.20M | 32.06M | 64.49M | 51.85M | 56.59M | 42.53M | 39.42M | -18.89M | -750.00K | -17.28M |
| Operating Income Ratio | 28.13% | -1.44% | -17.89% | -1.24% | 9.23% | 18.78% | 15.65% | 18.75% | 14.49% | 13.07% | -6.66% | -0.26% | -4.85% |
| Total Other Income/Expenses | 46.30M | -9.48M | -14.21M | -7.28M | -23.03M | -14.94M | -12.21M | -28.29M | -54.31M | -41.78M | -41.65M | -7.19M | -35.90M |
| Income Before Tax | 410.94M | 26.72M | -75.04M | -11.48M | 28.63M | 49.55M | 39.64M | 28.29M | -11.78M | -2.37M | -60.54M | -42.56M | -53.18M |
| Income Before Tax Ratio | 31.70% | 2.86% | -17.65% | -3.38% | 8.24% | 14.43% | 11.96% | 9.37% | -4.01% | -0.78% | -21.34% | -14.77% | -14.92% |
| Income Tax Expense | 84.28M | -1.35M | -3.76M | 1.99M | -3.04M | 9.03M | -83.75M | 1.53M | 2.97M | 1.20M | 1.01M | -555.00K | 84.08M |
| Net Income | 326.66M | 28.07M | -71.28M | -13.47M | 31.67M | 40.52M | 123.39M | 26.76M | -14.75M | -3.56M | -61.56M | -42.00M | -137.26M |
| Net Income Ratio | 25.20% | 3.00% | -16.76% | -3.97% | 9.12% | 11.80% | 37.23% | 8.87% | -5.02% | -1.18% | -21.70% | -14.58% | -38.52% |
| EPS | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 | -0.60 | -0.20 | -3.40 | -2.36 | -7.61 |
| EPS Diluted | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 | -0.60 | -0.20 | -3.34 | -2.32 | -7.61 |
| Weighted Avg Shares Out | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M | 24.44M | 17.81M | 18.08M | 17.79M | 18.03M |
| Weighted Avg Shares Out (Dil) | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.50M | 38.89M | 32.66M | 24.44M | 18.08M | 18.40M | 18.08M | 18.03M |
Why Lantheus Holdings Stock Won Big on Wednesday
Lantheus Announces Share Repurchase Program
Lantheus to Present at the Jefferies London Healthcare Conference
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
Lantheus Appoints Julie Eastland as New Board Member
Source: https://incomestatements.info
Category: Stock Reports